Press Releases ImmuPharma plc

Equities

IMM

GB0033711010

Market Closed - London S.E. Other stock markets 09:05:02 07/05/2024 pm IST			5-day change	1st Jan Change
2.02 ^GBX	+6.32%		-4.94%	+21.18%

29/04	Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director	CI
02/04	Immupharma jumps amid new IP strategy for P140 technology platform	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmuPharma : Incanthera Provides Commercial Update and Revenue Forecasts	26/03	PU
ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments	08/03	AQ
TR1 – Major Holding by Lanstead (Date: 28 December 2023)	02/01	PU
ImmuPharma : TR1 – Major holding by Lanstead	20/12	PU
ImmuPharma : Major shareholding by Lanstead via TR1	14/23/14	PU
ImmuPharma : Major shareholding from Lanstead Capital via TR1	06/23/06	PU
ImmuPharma : INTERIM RESULTS for the six months ended 30 June 2023	31/23/31	PU
ImmuPharma : Board strengthened Ahead of next phase of company progression	11/23/11	PU
ImmuPharma "absolutely delighted" to push on with new clinical trial	28/23/28	AQ
ImmuPharma : Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting	19/23/19	PU
Immupharma : Warrants Outstanding	16/23/16	PU
ImmuPharma : Notice of AGM & Annual Report & Accounts	06/23/06	PU
ImmuPharma "looking forward with quiet confidence" to FDA response	24/23/24	AQ
ImmuPharma : TR1 Lanstead holding 10 May 2023	11/23/11	PU
ImmuPharma : FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022	11/23/11	PU
ImmuPharma "looking forward" to upcoming FDA meetings	28/23/28	AQ
ImmuPharma : FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus	20/23/20	PU
ImmuPharma : receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP	12/23/12	PU
ImmuPharma : Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA	27/23/27	PU
ImmuPharma : Grant of Share Options	23/23/23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ImmuPharma plc

Equities

IMM

GB0033711010

Press Releases

Filters